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Caris Life Sciences; 445 N 5 th Street, Phoenix, AZ 85004 Activating mutations in both the KRAS and BRAF genes are associated with poor prognosis and nonresponse to anti-EGFR therapies in patients with advanced cancers. Clinical guidelines have recommended that KRAS mutational status be determined in all patients with metastatic colorectal cancer that are being considered for anti-EGFR therapies In this study a pathologist reviewed an
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therapies. In this study, a pathologist reviewed an H&E slide of each tumor sample and determined the percent tumor nuclei and percent necrosis. Each specimen was macrodissected and DNA was extracted. DNA was then amplified with primers flanking KRAS exon 2 (codons 12 and 13), and KRAS exon 3 (codon 61), and BRAF exon 15. Using the ABI3730 and Mutation Surveyor software, mutations Testing. Tumor samples were sectioned and scored for areas with >50% tumor nuclei by a pathologist and macrodissected by a technologist. Isolated DNA was PCR amplified and sequenced for mutations in codons 12, 13 and 61. The most common mutation identified in our laboratory was p.G12D (c.35G>A) and was 36.2% of all mutations observed. Bars in red represent mutations that are not analyzed in a commercially available PCR kit that is used in our laboratory. The codon 61 and other codon 12 and 13 mutations (frequency in parenthesis) were p.Q61H (8), p.Q61K (5), p.Q61L (3), p.Q61R (2), p.G13R(2), G12L (1), p.G13dup (1), and G13C (1).
FIGURE 3: KRAS Mutations Observed in Tumors Arising
From Different Tissues. Samples were classified based on the tissue of origin that was provided on the requisition form submitted with the sample. Consistent with previously reported results,~40% colorectal cancer and~60% of pancreatic cancer specimens were positive for mutations in KRAS. Notable "other sites" that were tested for KRAS mutations were skin(15), breast (13), stomach (9), cecum (8), esophagus (8), and neck (6). Other tissues tested were ovary (3), liver (3), stomach (2), bowel (2), lymph node (2), duodenum (1), jejunum (1), Ewing sarcoma (1), and other intestine (1).
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FIGURE 5: Variation In KRAS Mutations Observed in 37
Samples Tested By PCR. Tumor samples with 10-50% tumor were analyzed for KRAS mutations using a commercially available PCR based kit. This kit tested for the seven most common mutations listed on the chart above. Unlike results obtained from mutational analysis performed by sequencing, the most common mutation identified was p.G12V (c.35G>T). Overall,~40% of samples were positive for KRAS mutations as determined by PCR analysis.
